AIM: To document the impact on clinical practice in England of media attention around possible adverse effects of paroxetine. DESIGN: Analysis of national selective serotonin reuptake inhibitor (SSRI) prescribing trends and yellow-card adverse drug reaction reports, 2001-2004. RESULTS: From a steady state in 2001, paroxetine prescribing declined sharply from April 2002, coinciding with a USA regulatory action; the subsequent decline in paroxetine prescribing was 1.87% per month (95% confidence interval - 2.06, -1.68). Other SSRI prescribing increased by 1% per month until a major UK review of SSRIs in children in December 2003, after which prescribing plateaued. Media publicity was associated with short-term peaks in yellow-card reports related to paroxetine. CONCLUSION: Falls in paroxetine and other SSRI prescribing in the UK coincided, respectively, with regulatory communications from the USA and the UK, but associations may have noncausal or other explanations. Reports of adverse reactions to paroxetine appeared to increase after adverse media publicity about the drug.
AIM: To document the impact on clinical practice in England of media attention around possible adverse effects of paroxetine. DESIGN: Analysis of national selective serotonin reuptake inhibitor (SSRI) prescribing trends and yellow-card adverse drug reaction reports, 2001-2004. RESULTS: From a steady state in 2001, paroxetine prescribing declined sharply from April 2002, coinciding with a USA regulatory action; the subsequent decline in paroxetine prescribing was 1.87% per month (95% confidence interval - 2.06, -1.68). Other SSRI prescribing increased by 1% per month until a major UK review of SSRIs in children in December 2003, after which prescribing plateaued. Media publicity was associated with short-term peaks in yellow-card reports related to paroxetine. CONCLUSION: Falls in paroxetine and other SSRI prescribing in the UK coincided, respectively, with regulatory communications from the USA and the UK, but associations may have noncausal or other explanations. Reports of adverse reactions to paroxetine appeared to increase after adverse media publicity about the drug.
Authors: M M Stahl; M Lindquist; M Pettersson; I R Edwards; J H Sanderson; N F Taylor; A P Fletcher; J S Schou Journal: Eur J Clin Pharmacol Date: 1997 Impact factor: 2.953
Authors: Juan Francisco Hernandez; Aukje K Mantel-Teeuwisse; Ghislaine J M W van Thiel; Svetlana V Belitser; Jan Warmerdam; Vincent de Valk; Jan A M Raaijmakers; Toine Pieters Journal: PLoS One Date: 2012-09-20 Impact factor: 3.240
Authors: J F Hernandez; A K Mantel-Teeuwisse; G J M W van Thiel; S V Belitser; J A M Raaijmakers; T Pieters Journal: BMJ Open Date: 2011-12-06 Impact factor: 2.692
Authors: Sameer Jauhar; Joseph Hayes; Guy M Goodwin; David S Baldwin; Philip J Cowen; David J Nutt Journal: J Psychopharmacol Date: 2019-05-21 Impact factor: 4.562
Authors: Neil M Davies; David Gunnell; Kyla H Thomas; Chris Metcalfe; Frank Windmeijer; Richard M Martin Journal: J Clin Epidemiol Date: 2013-09-24 Impact factor: 6.437